159 related articles for article (PubMed ID: 15723622)
1. Recent advances in pretargeted radioimmunotherapy.
Gruaz-Guyon A; Raguin O; Barbet J
Curr Med Chem; 2005; 12(3):319-38. PubMed ID: 15723622
[TBL] [Abstract][Full Text] [Related]
2. Pretargeted radioimmunotherapy of cancer: progress step by step.
Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
[TBL] [Abstract][Full Text] [Related]
3. Pretargeted radioimmunotherapy.
Meredith RF; Buchsbaum DJ
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S57-9. PubMed ID: 16979441
[TBL] [Abstract][Full Text] [Related]
4. Pretargeting: A Path Forward for Radioimmunotherapy.
Cheal SM; Chung SK; Vaughn BA; Cheung NV; Larson SM
J Nucl Med; 2022 Sep; 63(9):1302-1315. PubMed ID: 36215514
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens.
Reilly RM
J Nucl Med; 2006 Feb; 47(2):196-9. PubMed ID: 16455623
[No Abstract] [Full Text] [Related]
6. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies.
Chang CH; Sharkey RM; Rossi EA; Karacay H; McBride W; Hansen HJ; Chatal JF; Barbet J; Goldenberg DM
Mol Cancer Ther; 2002 May; 1(7):553-63. PubMed ID: 12479274
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?
Goldenberg DM; Chang CH; Sharkey RM; Rossi EA; Karacay H; McBride W; Hansen HJ; Chatal JF; Barbet J
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):777-80. PubMed ID: 12574971
[No Abstract] [Full Text] [Related]
8. Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?
Paganelli G; Chinol M
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):773-6. PubMed ID: 12557049
[No Abstract] [Full Text] [Related]
9. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
Gautherot E; Rouvier E; Daniel L; Loucif E; Bouhou J; Manetti C; Martin M; Le Doussal JM; Barbet J
J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323
[TBL] [Abstract][Full Text] [Related]
10. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
[TBL] [Abstract][Full Text] [Related]
11. Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
Mirallié E; Saï-Maurel C; Faivre-Chauvet A; Regenet N; Chang CH; Goldenberg DM; Chatal JF; Barbet J; Thedrez P
Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):901-9. PubMed ID: 15864584
[TBL] [Abstract][Full Text] [Related]
12. Pretargeted radioimmunotherapy with α-particle emitting radionuclides.
Lindegren S; Frost SH
Curr Radiopharm; 2011 Jul; 4(3):248-60. PubMed ID: 22201711
[TBL] [Abstract][Full Text] [Related]
13. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
[TBL] [Abstract][Full Text] [Related]
14. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.
Sharkey RM; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
Semin Nucl Med; 2010 May; 40(3):190-203. PubMed ID: 20350628
[TBL] [Abstract][Full Text] [Related]
15. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
16. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
17. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
[TBL] [Abstract][Full Text] [Related]
19. Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
Zhu H; Jain RK; Baxter LT
J Nucl Med; 1998 Jan; 39(1):65-76. PubMed ID: 9443740
[TBL] [Abstract][Full Text] [Related]
20. A universal pretargeting system for cancer detection and therapy using bispecific antibody.
Sharkey RM; McBride WJ; Karacay H; Chang K; Griffiths GL; Hansen HJ; Goldenberg DM
Cancer Res; 2003 Jan; 63(2):354-63. PubMed ID: 12543788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]